He will succeed Reto Suter, who has led the Siegfried Group as CEO ad interim since the departure of Wolfgang Wienand on May 1, 2024. Suter will now focus on his role as Chief Financial Officer for Siegfried. Wienand will become CEO of Swiss competitor Lonza.

Marcel Imwinkelried joined the Siegfried Group in January 2021 as Multi-Site Head for the Drug Products sites in Barbera del Valle s and El Masnou (Barcelona) and Irvine (California) and was appointed Chief Operating Officer Drug Products in October 2021. Previously, he had worked for Novartis since 2005 in various roles with increasing responsibility and was appointed Global Head Technical Operations Solids in 2018.

"Over the past three months, we have conducted intensive interviews with qualified external and internal candidates," commented Andreas Casutt, Chairman of the Board of Directors. "Marcel impressed us not only with his professional track record, but also with his personality and strong leadership skills. As COO of our Drug Products division and a member of the Executive Board, he has already made significant contributions to Siegfried’s success over the past three years. I am convinced that under his leadership Siegfried will continue its journey of growth.”